OncoMatch/Clinical Trials/NCT06733948
ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients
Is NCT06733948 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dental stent for nasopharyngeal carcinoma.
Treatment: Dental stent — Primary objective: Evaluate and compare incidence of acute and long-term taste dysfunction in chemoradiation plus dental stent group vs. chemoradiation group, using objective-measured taste strip test, and patient-reported taste ability and toxicity. Secondary objectives: 1. Evaluate and compare incidence of acute and long-term toxicities (excluding taste) and patient-reported quality of life between chemoradiation plus dental stent group and chemoradiation group. 2. Evaluate and compare tumor response, overall survival, and failure-free survival between chemoradiation plus dental stent group and chemoradiation group. 3. Analyze dosimetric parameters of taste bud bearing tongue mucosa, ipsilateral/ contralateral parotid and submandibular glands extracted from RT plans and correlate with taste impair
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TXN0, TXN1, TXN2, TXN3
Tumours staged as T1-4N+/TxN0-3. No sign of distant metastasis (M0).
Performance status
KARNOFSKY OR ECOG 70–1
Karnofsky Performance Status ≥ 70 or ECOG < 2
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: except for non-melanomatous skin cancers outside the intended RT treatment area
Received RT previously (except for non-melanomatous skin cancers outside the intended RT treatment area)
Cannot have received: surgery
Exception: except diagnostic
Patients who received previous surgery (except diagnostic) for the primary tumours or lymph nodes or history of glossectomy
Cannot have received: chemotherapy
Patients who received previous...chemotherapy for the primary tumours or lymph nodes
Lab requirements
Blood counts
≥ 3 × 10^9/L leucocytes; ≥ 1.5 × 10^9/L neutrophils; ≥ 9 g/dL haemoglobin; ≥ 100 × 10^9/L platelets
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
ALT and AST < 1.5x ULN; ALP < 2.5x ULN; Bilirubin < ULN
Adequate bone marrow function by peripheral blood counts... Normal liver function... Renal function: Creatinine clearance at ≥60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06733948 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, surgery, chemotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage TXN0 or TXN1 or TXN2 or TXN3 is required.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 21 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages